Press "Enter" to skip to content

Patent delisted for Boehringer Ingelheim drug OFEV

0
Copyright © DrugPatentWatch. Originally published at Patent delisted for Boehringer Ingelheim drug OFEV

Annual Drug Patent Expirations for OFEV
Ofev is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and twelve patent family members in fifty-one countries.

The generic ingredient in OFEV is nintedanib esylate. One supplier is listed for this compound. Additional details are available on the nintedanib esylate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at Patent delisted for Boehringer Ingelheim drug OFEV
    Get the DrugPatentWatch Daily Briefing

    ✓ Patent Expirations and Generic Entry

    ✓ Insightful Articles & Case Studies

    ✓ Patent Litigation & Challenges

    ✓ 505(b)(2) & Biosimilars

    ✓ Industry Trends

    Do NOT follow this link or you will be banned from the site!